Knock down of the toxic BH3 domain protein BID, which is downstream of CD95, FADD and pro-caspase 8, significantly reduced the ability of regorafenib alone or in combination with aramchol to cause autophagosome and autolysosome formation and to kill tumor cells. Here, BID is linked to neoplasm.